title: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
abstract: Immune stimulatory oligodeoxynucleotides (ODN) with unmethylated CpG motifs are potent inducers of both innate and adaptive immunity. It initially appeared that a single type of optimal CpG motif would work in all applications. We now report that specific motifs of CpG ODN can vary dramatically in their ability to induce individual immune effects and that these differences impact on their antitumor activity in different tumor models. In particular, a distinct type of CpG motif, which has a chimeric backbone in combination with poly(G) tails, is a potent inducer of NK lytic activity but has little effect on cytokine secretion or B cell proliferation. One such NK-optimized CpG ODN (1585) can induce regression of established melanomas in mice. Surprisingly, no such therapeutic effects were seen with CpG ODN optimized for activation of B cells and Th1-like cytokine expression (ODN 1826). The therapeutic effects of CpG 1585 in melanoma required the presence of NK but not T or B cells and were not associated with the induction of a tumor-specific memory response. In contrast, CpG 1826, but not CpG 1585, was effective at inducing regression of the EL4 murine lymphoma; this rejection was associated with the induction of a memory response and although NK cells were necessary, they were not sufficient. These results demonstrate that selection of optimal CpG ODN for cancer immunotherapy depends upon a careful analysis of the cellular specificities of various CpG motifs and an understanding of the cellular mechanisms responsible for the antitumor activity in a particular tumor.
authors.affiliation: Department of Veterans Affairs Medical Center, Iowa City, IA 52246, USA. ballasz@uiowa.edu
authors.forename: Z K
authors.initials: ZK
authors.lastname: Ballas
authors.forename: A M
authors.initials: AM
authors.lastname: Krieg
authors.forename: T
authors.initials: T
authors.lastname: Warren
authors.forename: W
authors.initials: W
authors.lastname: Rasmussen
authors.forename: H L
authors.initials: HL
authors.lastname: Davis
authors.forename: M
authors.initials: M
authors.lastname: Waldschmidt
authors.forename: G J
authors.initials: GJ
authors.lastname: Weiner
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000502:physiology; D007156:Immunologic Memory; D018664:Interleukin-12 / Q000502:physiology; D007694:Killer Cells, Natural / Q000502:physiology; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000276:immunology; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000502:physiology
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D018664:Interleukin-12